Filing Details
Kymera Therapeutics, Inc. (NASDAQ:KYMR) filed a Form 8-K with the Securities and Exchange Commission on June 25, 2026, disclosing a material event.
8k filedNASDAQ:KYMR
Kymera Therapeutics, Inc. (KYMR) Reports Material Event to SEC
Filing Details Kymera Therapeutics, Inc. (NASDAQ:KYMR) filed a Form 8-K with the Securities and Exchange Commission on June 25, 2026, disclosing a material event. Market Context…
Market Context
Kymera Therapeutics, Inc.'s stock currently trades at $116.46 with a market capitalization of $6.3B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Kymera Therapeutics, Inc.'s stock.
All SEC filings for Kymera Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View KYMR Stock Page
Frequently Asked Questions
Where can I read KYMR's SEC filings?
Browse all filings on our KYMR SEC filings page.
What types of SEC filings does Kymera Therapeutics, Inc. file?
Public companies like Kymera Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.